Login / Signup

Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors.

Yoriko Yamashita-KashimaKeigo YorozuTakaaki FujimuraNatsumi KawasakiMitsue KurasawaShigeki YoshiuraNaoki HaradaOsamu KondohYasushi Yoshimura
Published in: International journal of hematology (2022)
Coadministration of bendamustine in obinutuzumab retreatment may be effective against obinutuzumab-resistant tumors.
Keyphrases
  • chronic lymphocytic leukemia